Serum Pepsinogen Values and Helicobacter pylori Status among Control Subjects of a Nested Case-Control Study in the JACC study

Kikuchi, Shogo; Yagyu, Kiyoko; Obata, Yuki; Lin, Yingsong; Yatsuya, Hiroshi; Hoshiyama, Yoshiharu; Kondo, Takaaki; Sakata, Kiyoshi; Mizoue, Tetsuya; Tokui, Noritaka; Fujino, Yoshihisa; Tamakoshi, Akiko; Toyoshima, Hideaki; Ishibashi, Teruo; Hayakawa, Norihiko; Yoshimura, Takesumi

doi:10.2188/jea.15.s126

Cited by 21 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our present study demonstrated that patients with H. pylori ‐related non‐AG (i.e. SG and SG‐IM), showed significantly greater levels of sPGII than their H. pylori ‐seronegative counterparts, which was in general agreement with previous reports 31,32 . A positive correlation between sPGII and H. pylori status was also observed in patients with GC or precancerous lesions (i.e.…”

Section: Discussionsupporting

confidence: 92%

Serum pepsinogen II: A neglected but useful biomarker to differentiate between diseased and normal stomachs

Sun

Gong

et al. 2011

J of Gastro and Hepatol

View full text Add to dashboard Cite

We demonstrated that the mean values of sPGII in a healthy Chinese population are 7 microg/L and 6 microg/L for males and females, respectively. sPGII significantly increases in diseased and H. pylori-infected stomach, and the best sPGII cut-off value is 8.25 microg/L in the differentiation between patients with healthy and diseased stomach mucosae. Furthermore, Chinese patients with sPGII greater than 10.25 microg/L are at greater risk of various H. pylori-related gastropathies, and are therefore prior candidates for gastro-protection therapy.

show abstract

Section: Discussionsupporting

confidence: 92%

Serum pepsinogen II: A neglected but useful biomarker to differentiate between diseased and normal stomachs

Sun

Gong

et al. 2011

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Measurement of pepsinogen serum levels was carried out by 11 studies in Japan (33,35,44,49,(51)(52)(53)(55)(56)(57)(58), two studies among Japanese living abroad (48,50), several others in Europe [United Kingdom (31,40), Italy (32), Finland (43,46,54) and the Netherlands (47)], two in the United States (29,45), and one in New Zealand (59). International comparative studies included population samples from 13 (37), 4 (60), and 2 (42) nations, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…Furthermore, the cutoff values widely differed among the studies: 70 ng/mL (indicating mild, moderate, and severe CAG) was most frequently used as PG I threshold, but there are also studies using 17, 20, or 25 ng/mL (indicating exclusively severe CAG) and one study each with 30, 49, and 50 ng/mL, a pattern that inevitably leads to differences in prevalence estimates. In contrast, the threshold for the PG I/PG II ratio was 3.0 (or 2.9) mostly, but a threshold of 1.3, 1.6, 2.0, and 2.5 was also used in single studies (40,42,47,49,58).…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Chronic Atrophic Gastritis in Different Parts of the World

Weck

Brenner

2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

132

View full text Add to dashboard Cite

Chronic atrophic gastritis (CAG) is a well-established precursor of intestinal gastric cancer, but epidemiologic data about its occurrence are sparse. We provide an overview on studies that examined the prevalence of CAG in different parts of the world. Articles containing data about the prevalence of chronic atrophic gastritis in unselected population samples and published until November 2005 were identified by searching the MEDLINE database. Furthermore, the references in the identified publications were screened for additional suitable studies. Studies comprising at least 50 subjects were included. Forty-one studies providing data on the prevalence of CAG in unselected population samples could be identified. CAG was determined by gastroscopy in 15 studies and by pepsinogen serum levels in 26 studies.Although results are difficult to compare due to the various definitions of CAG used, a strong increase with age, the lack of major gender differences, and strong variations between populations and population groups (in particular, relatively high rates in certain Asian populations) could be observed quite consistently. We conclude that CAG is relatively common among older adults in different parts of the world, but large variations exist. Large-scale international comparative studies with standardized methodology to determine CAG are needed to provide a coherent picture of the epidemiology of CAG in various populations. Noninvasive measurements of CAG by pepsinogen levels may be particularly suited for that purpose. (Cancer Epidemiol Biomarkers Prev 2006;15(6):1083 -94)

show abstract

“…It has been demonstrated that the percentages of those with severe serological atrophy increased with age from 10% in those aged 40-49 years to 38% in those aged 70 and more, and the percentages of those with mild serological atrophy were about 30%, independent of age. 68 Although the prevalence of H. pylori infection in Japan has fallen in recent years, 22 those who are infected remain at risk of gastric cancer. An H. pylori infection was detected in up to 70% of the population by the age of 40 years in Japan.…”

Section: Advantages and Disadvantages Of Serum Pepsinogen Methodsmentioning

confidence: 99%

“…67 reported that among subjects younger than 40 years old, early stage carcinoma has a stronger association with H. pylori than advanced carcinoma, and intestinal‐ and diffuse‐type carcinomas have an association with H. pylori . It has been demonstrated that the percentages of those with severe serological atrophy increased with age from 10% in those aged 40–49 years to 38% in those aged 70 and more, and the percentages of those with mild serological atrophy were about 30%, independent of age 68 . Although the prevalence of H. pylori infection in Japan has fallen in recent years, 22 those who are infected remain at risk of gastric cancer.…”

Section: Gastric Cancer Screeningmentioning

confidence: 99%

Using serum pepsinogens wisely in a clinical practice

Miki

Urita

2007

J of Digest Diseases

View full text Add to dashboard Cite

Serum pepsinogen (PG) has been used as biomarkers of gastric inflammation and mucosal status, including atrophic change, before the discovery of Helicobacter pylori (H. pylori). Serum pepsinogen I (PG I) and pepsinogen II (PG II) levels are known to increase in the presence of H. pylori-related nonatrophic chronic gastritis. The measurement of serum PG provides much information on the presence of intestinal metaplasia as well as atrophic gastritis. The eradication of H. pylori provokes a significant change in serum PG values: it reduces both PG I and PG II and elevates the PG I to PG II ratio. Recently, the serum PG test method has been the first screening step in Japan, as well as photofluorography. Serum PG tests are used to screen for high risk subjects with atrophic gastritis, rather than as a test for cancer itself. Unlike photofluorography or endoscopy, serum PG screening can identify nonulcerated differentiated asymptomatic cancer, irrespective of the size and location of the lesion. Most cases detected by the PG method are asymptomatic early gastric cancers and are limited to the mucosa, which are particularly well suited for endoscopic treatment. The PG method can contribute greatly to the patients' quality of life.KEY WORDS: atrophic gastritis, gastric cancer screening, non-atrophic gastritis, serum pepsinogens I and II.

show abstract

Serum Pepsinogen Values and Helicobacter pylori Status among Control Subjects of a Nested Case-Control Study in the JACC study

Cited by 21 publications

References 27 publications

Serum pepsinogen II: A neglected but useful biomarker to differentiate between diseased and normal stomachs

Serum pepsinogen II: A neglected but useful biomarker to differentiate between diseased and normal stomachs

Prevalence of Chronic Atrophic Gastritis in Different Parts of the World

Using serum pepsinogens wisely in a clinical practice

Contact Info

Product

Resources

About